Leede Financial Has Negative View of TSE:MDP FY2026 Earnings

Key Points

• Leede Financial has reduced its FY2026 earnings per share (EPS) estimate for Medexus Pharmaceuticals to $0.14, down from the previous estimate of $0.21, while the consensus estimate stands at $0.16.
• Alliance Global Partners has upgraded Medexus Pharmaceuticals to a "strong-buy" rating, with the company holding a consensus rating of "Buy" and a target price of C$5.49.
• As of Thursday, Medexus Pharmaceuticals shares traded at C$2.65, down 0.7%, with a 52-week trading range of C$1.71 to C$5.56.

Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Equities research analysts at Leede Financial reduced their FY2026 earnings per share estimates for Medexus Pharmaceuticals in a report issued on Wednesday, August 13th. Leede Financial analyst D. Loe now anticipates that the company will post earnings of $0.14 per share for the year, down from their prior estimate of $0.21. The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share. Leede Financial also issued estimates for Medexus Pharmaceuticals' FY2027 earnings at $0.51 EPS and FY2028 earnings at $0.82 EPS.

Separately, Alliance Global Partners upgraded Medexus Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 11th. Four investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of C$5.49.

Medexus Pharmaceuticals Stock Performance

TSE MDP traded down C$0.10 on Thursday, reaching C$2.75. The stock had a trading volume of 10,165 shares, compared to its average volume of 72,955. The stock has a market cap of C$61.57 million, a P/E ratio of 13.15 and a beta of 1.96. The business's 50-day moving average price is C$2.92 and its 200 day moving average price is C$2.79. Medexus Pharmaceuticals has a 12-month low of C$1.71 and a 12-month high of C$5.56.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.